NCT02304783View on ClinicalTrials.gov

Oral NSAI Versus Paracetamol or Placebo as a Second Line Treatment for Renal Colics

PHASE3CompletedINTERVENTIONAL
Enrollment

1,400

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

June 30, 2021

Study Completion Date

December 31, 2021

Conditions
Renal Colic
Interventions
DRUG

Piroxicam

Patients allocated to this arm received, as a second line treatment of renal colics, a five days treatment with 20 mg piroxicam associated with placebo per day and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.

DRUG

Placebo

Patients allocated to this arm received a five days treatment with Placebo and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.

DRUG

paracetamol

Patients allocated to this arm received a five days treatment with Paracetamol and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.

Trial Locations (1)

5050

Emergency Department of University Hospital of Monastir, Monastir

All Listed Sponsors
lead

University of Monastir

OTHER

NCT02304783 - Oral NSAI Versus Paracetamol or Placebo as a Second Line Treatment for Renal Colics | Biotech Hunter | Biotech Hunter